Revelation Biosciences financials
$0.8140−5.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$3.7M | -$3.1M | -$2.6M | -$1.9M | -$2.5M | -$2.1M | -$1.8M | -$1.8M | -$2.5M | -$1.9M | -$2.3M | -$2.8M |
| Net income | -$3.3M | -$8.7M | -$2.5M | -$4.7M | -$5.6M | -$2.1M | -$1.7M | -$2.2M | -$8.4M | -$2.7M | -$2.2M | -$2.6M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.87 | $-2.71 | — | $-7.08 | $-28.04 | $-25.34 | $-39.22 | $-160.60 | $-985.08 | $-472.44 | $-1795.89 | $-1908.48 |
| EBITDA | -$3.7M | -$3.1M | -$2.6M | -$1.9M | -$2.5M | -$2.1M | -$1.7M | -$1.8M | -$2.5M | -$1.9M | -$2.3M | -$2.8M |
| Operating cash flow | -$2.6M | -$3.2M | -$2.0M | -$1.6M | -$1.9M | -$2.8M | -$3.7M | -$9.3M | -$2.5M | -$2.8M | -$2.0M | -$1.7M |
| Free cash flow | -$2.6M | -$3.3M | -$2.0M | -$1.6M | -$1.9M | -$2.8M | -$3.8M | -$9.3M | -$2.5M | -$2.9M | -$2.0M | -$1.7M |
| Diluted shares | 3.8M | 3.2M | — | 0.7M | 0.2M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.5M | $14.1M | $10.7M | $12.7M | $5.2M | $3.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $12.5M | $15.0M | $11.6M | $12.9M | $5.4M | $4.0M |
| Total liabilities | $2.4M | $2.1M | $2.7M | $1.9M | $1.6M | $1.1M |
| Shareholders' equity | $10.1M | $13.0M | $8.9M | $11.0M | $3.8M | $2.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology